Guardant Health
Sven Duenwald is an accomplished professional with extensive experience in technology development and product management within the biotechnology and genomics sectors. Currently serving as Vice President of Screening Technology Development at Guardant Health since May 2019, Sven has also held roles including Senior Director of Technology Development at the same company and Senior Director of Product Development for Clinical Genomics at Illumina. Previous positions include Director of Product Development at Guardant Health and various leadership roles at Illumina and Genentech, where Sven contributed to advancements in reproductive and genetic health. Sven's career commenced at Sirna Therapeutics (Merck), where significant experience in methods development and automation was gained. Sven holds a Bachelor of Science degree in Chemistry from the University of Washington.
This person is not in any teams
Guardant Health
14 followers
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum.